- Home
- COMP vs MRUS Comparison
COMP vs MRUS Comparison
Compare COMP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COMP | MRUS |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.1B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | COMP | MRUS |
|---|---|---|
| Price | $10.67 | $91.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $10.83 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 9.7M | 1.2M |
| Earning Date | 02-17-2026 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,642,200,000.00 | $56,606,000.00 |
| Revenue This Year | $25.14 | $56.08 |
| Revenue Next Year | $12.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.27 | ★ 57.54 |
| 52 Week Low | $5.10 | $33.19 |
| 52 Week High | $11.07 | $97.14 |
Technical Indicators
Market Signals| Indicator | COMP | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 14.70 |
| Support Level | $10.44 | $96.78 |
| Resistance Level | $10.79 | $97.00 |
| Average True Range (ATR) | 0.36 | 0.85 |
| MACD | -0.08 | -0.56 |
| Stochastic Oscillator | 53.48 | 28.60 |
Price Performance
Historical ComparisonAbout COMP Compass Inc.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.